# Kyowa Kirin

Kyowa Kirin is a Corporate Investor based in Tokyo, Japan.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Tokyo, Japan
- **Region:** Asia
- **Address:** 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** kyowakirin.co.jp
- **LinkedIn:** https://www.linkedin.com/company/kyowa-kirin-co-ltd
- **Wikidata:** Q6452254

## Regulatory record

- **Reports private funds:** No

## About

Kyowa Kirin was formed in 2008 through the merger of Kyowa Hakko Kogyo and Kirin Pharma, two entrenched names in Japanese fermentation and biotechnology. Kirin Holdings retains a 53.77% controlling stake, anchoring the firm within one of Japan's largest beverage-to-pharma conglomerates. Chairman and CEO Masashi Miyamoto has led the combined entity since inception, while President and COO Abdul Mullick is set to assume the CEO role in March 2026. The firm focuses its corporate venture and strategic partnership activity on its four core therapeutic areas: oncology, nephrology, immunology, and the central nervous system. Its investment posture is purely strategic — taking equity stakes and forming R&D collaborations with biotechnology companies whose assets align with its pipeline. A flagship partnership with Amgen Inc. is co-developing rocatinlimab (KHK4083), an anti-OX40 monoclonal antibody for atopic dermatitis. North American deal sourcing and alliance management run through hubs in Princeton, New Jersey, and a specialized research institute in La Jolla, California — placing the firm close to both the US capital markets and the San Diego biotech cluster. Operational infrastructure underscores the firm's hybrid pharma-investor model. Kyowa Kirin owns biologics manufacturing plants in Sanford, North Carolina, and across three Japanese prefectures, allowing it to scale production for portfolio companies it backs. In the EMEA region, a joint venture with Grünenthal manages the International Established Medicines portfolio — a cash-generative, non-core asset base that frees resources for pipeline investment. The firm also maintains a long-term partnership with the Health and Global Policy Institute (HGPI), signaling an interest in shaping market-access frameworks in Asia. What distinguishes Kyowa Kirin is its identity as a balance-sheet corporate venture investor embedded within a publicly listed operating company. Unlike standalone venture arms that raise third-party funds, Kyowa Kirin invests from its own P&L, aligning capital deployment directly with internal R&D priorities.

## Sectors

- Oncology
- Nephrology
- Immunology
- Central Nervous System

## Offices

- Princeton, NJ, United States
- La Jolla, CA, United States

## People

- Masashi Miyamoto — Chairman and Chief Executive Officer
- Abdul Mullick — President and Chief Operating Officer; designated CEO effective March 2026

## Questions

### Who controls Kyowa Kirin's investment and strategic decisions?

Chairman and CEO Masashi Miyamoto has run the firm since the 2008 merger of Kyowa Hakko Kogyo and Kirin Pharma. His designated successor, Abdul Mullick, currently serves as President and COO and will take over as CEO in March 2026. Kirin Holdings holds a 53.77% ownership stake and exerts ultimate parent-level control.

### What is the firm's geographic focus for deal sourcing?

Kyowa Kirin sources deals globally but maintains a strong operational footprint in North America through offices in Princeton, New Jersey, and a research institute in La Jolla, California. The La Jolla presence is particularly significant — it places the firm inside the San Diego biotechnology ecosystem. The company also manages an established medicines portfolio across the EMEA region through a joint venture with Grünenthal.

### Does Kyowa Kirin invest through fund commitments or only direct deals?

Kyowa Kirin pursues direct strategic investments and R&D collaborations rather than committing capital to external venture funds. The firm licenses and co-develops assets with portfolio companies, using its in-house manufacturing plants in Japan and North Carolina to support commercialization. No publicly disclosed fund-of-funds activity exists.

## Related profiles

- [Kyoto Shinkin Bank](https://altss.com/profile/kyoto-shinkin-bank)
- [Kyowon Life](https://altss.com/profile/kyowon-life)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/kyowa-kirin

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology